epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.
EPI-118, Phase II. In start-up
Treatment-resistant major depressive disorder
FBK-118 against placebo in treatment-resistant major depressive disorder. Sponsor: Fabrikam Neuroscience (fictional), CNS and psychiatry.
Where EPI-118 stands on September 30th 2026
Randomised0of 243 needed
Sites open0of 135 planned
Median forecast finishFeb 2029Deadline May 2029
FinishOn timeMedian forecast 3 months before the deadline.Open the plan
EnrolmentToo earlyToo few patients expected yet to judge.Open KPIs
SitesToo earlyNo site has been open long enough to judge.Open Sites
KRIs0 of 135 flaggedSites over at least one KRI threshold, each a candidate for a call, a targeted review or a visit.Open KRIs
QTLsToo earlyToo few patients yet to judge the study-level limits.Open QTLs